Exelixis Inc.'s strong start for Cabometyx (cabozantinib) in kidney cancer in the second quarter boosts expectations for the drug itself and may signal a changing of the guard in kidney cancer as new products sweep in.
Cabozantinib was initially approved for medullary thyroid cancer in November 2012 and is marketed as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?